Drug Profile
Thalidomide - Celgene Corporation
Alternative Names: Alpha-N-phthalimidoglutarimide; CC-2001; FPF-300; K-17; NSC-66847; Synovir; Thaled; Thalidomide Celgene; Thalidomide Pharmion; ThalomidLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator EntreMed; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); University of Pennsylvania
- Developer Celgene Corporation; Erkim; Fujimoto Pharmaceutical; Grunenthal; Laphal; Weill Cornell Medical College
- Class Antifibrotics; Antileprotics; Antineoplastics; Antitussives; Indoles; Phthalimides; Piperidones; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Leprosy; Multiple myeloma
- Phase II Graft-versus-host disease; Waldenstrom's macroglobulinaemia
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 29 Dec 2020 Weill Medical College of Cornell University completes a phase II trial in Chronic lymphocytic leukaemia (combination therapy) in USA (PO) (NCT01125176)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 02 Jul 2019 No development reported - Preregistration for Leprosy in Hong Kong (PO)